Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug-induced thrombocytopenia
- 11 June 2020
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 135 (24), 2146-2158
- https://doi.org/10.1182/blood.2019003749
Abstract
Immunomodulatory drugs (IMiDs) are key agents for the treatment of multiple myeloma and myelodysplastic syndrome with chromosome 5q deletion. IMiDs exert their pleiotropic effects through the recruitment of neosubstrates to cereblon, a substrate receptor of the E3 ubiquitin ligase complex; therefore, identification of cell-specific neosubstrates is important to understand the effects of IMiDs. In clinical practice, IMiDs induce thrombocytopenia, which frequently results in the discontinuation of IMiD treatment. In the current study, we sought to identify the molecular mechanism underlying thrombocytopenia induced by IMiD treatment. We found that IMiDs strongly impaired proplatelet formation, a critical step in functional platelet production, through the inhibition of autocrine estradiol signaling in human megakaryocytes. Furthermore, we identified aromatase, an indispensable enzyme for estradiol biosynthesis, as a novel neosubstrate of cereblon. IMiDs promoted the recruitment of aromatase to cereblon, resulting in the degradation of aromatase in a proteasome-dependent manner. Finally, aromatase was significantly degraded in the bone marrow of patients with multiple myeloma who developed thrombocytopenia with IMiD treatment. These data suggest that aromatase is a neosubstrate of cereblon that is responsible for IMiD-induced thrombocytopenia.This publication has 50 references indexed in Scilit:
- Cereblon and its downstream substrates as molecular targets of immunomodulatory drugsInternational Journal of Hematology, 2016
- Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDSNature, 2015
- Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomideNature, 2014
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros ProteinsScience, 2014
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma CellsScience, 2014
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2013
- Identification of a Primary Target of Thalidomide TeratogenicityScience, 2010
- Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North AmericaThe New England Journal of Medicine, 2007
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple MyelomaThe New England Journal of Medicine, 2007
- Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q DeletionThe New England Journal of Medicine, 2006